US6036931029 - Common Stock
MINK THERAPEUTICS INC
NASDAQ:INKT (4/29/2024, 7:07:09 PM)
After market: 0.9799 +0.03 (+3.14%)0.9501
+0.02 (+2.44%)
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company is headquartered in New York City, New York and currently employs 37 full-time employees. The company went IPO on 2021-10-15. The company is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
MINK THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK
P: 12129948250
Employees: 37
Website: https://www.minktherapeutics.com
MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms...
INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MiNK Therapeutics (NASDAQ:INKT) just reported results for the fourth quarter of...
Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced...
Here you can normally see the latest stock twits on INKT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: